Stockreport

Senseonics Announces FDA Approval for a Non-Adjunctive Indication (Dosing Claim) for the Eversense® 90-day CGM System

Senseonics Holdings, Inc.  (SENS) 
Last senseonics holdings, inc. earnings: 3/12 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: senseonics.com/investor-relations
PDF With a non-adjunctive claim, Eversense users will soon be able to manage their diabetes dosing decisions without confirming with fingersticks [Read more]